research News

San Francisco, Calif. – A clinical trial that will test three drugs concurrently, and could include more, represents new hope for patients with progressive supranuclear palsy (PSP), an incurable neurodegenerative disorder that usually kills within seven years after symptoms start. Researchers hope the trial, which will be led by UC...
Tianjin, China – A transformative study has provided a profound understanding of glioblastoma’s molecular subtypes, revealing the nuances of cellular heterogeneity and the mechanisms behind resistance to treatment. This critical research not only enhances our comprehension of this aggressive cancer but also opens new frontiers for the precision-targeting of therapies,...
AURORA, Colo. – A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for understanding and treating Duchenne Muscular Dystrophy (DMD). Published in the December issue of the Journal of Biological Chemistry, researchers characterize...
MIAMI, Florida – Researchers have developed a functional precision medicine approach that targets cancer by combining genetic testing with a new way to test individual drugs on tumor samples. The results of the clinical study were published today in Nature Medicine. This combined approach, developed by Florida International University cancer researcher...
CHICAGO, Illinois – Researchers have identified a new way to screen genes that cause several different types of cancers to grow, identifying particularly promising targets for precision oncology in oral and esophageal squamous cancers. The study, published in this month’s issue of Cell Reports, used 3-dimensional models of organ tissues called organoids...
– GTB-5550, which harbors wild-type IL-15, and BiKE display broad activity against B7-H3-expressing tumors – Compared to monomeric IL-15, GTB-5550 shows CD16-dependent metabolic activation of NK cells BEVERLY HILLS, Calif., – GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical-stage immuno-oncology company focused on developing innovative therapeutics based on the...